Table 1A.
Patient characteristics in stent and non-stent treatment groups.
| Demographic and Clinical Characteristics | All (n = 2162) | Stent Based (n = 1007) | Non-Stent Based (n = 1155) | P-Value |
|---|---|---|---|---|
| Age (years) | 66.2 ± 10.2 | 64.6 ± 9.6 | 67.3 ± 10.4 | <.001 |
| Female | 532 (24.6%) | 208 (20.7%) | 324 (28.1%) | <.001 |
| Caucasians | 1435 (66.4%) | 675 (67.0%) | 884 (62.6%) | .61 |
| African-Americans | 460 (21.3%) | 214 (21.3%) | 246 (21.3%) | |
| Hispanics | 187 (8.7%) | 84 (8.3%) | 103 (8.9%) | |
| Other | 33 (1.5%) | 17 (1.7%) | 16 (1.4%) | |
| Unknown race | 47 (2.2%) | 17 (1.7%) | 30 (2.6%) | |
| Hypertension | 1925 (89.0%) | 903 (89.7%) | 1022 (88.5%) | .38 |
| Diabetes mellitus | 1102 (51.0%) | 512 (50.8%) | 590 (51.1%) | .91 |
| Hyperlipidemia | 1761 (81.5%) | 817 (81.1%) | 944 (81.7%) | .72 |
| Chronic kidney disease | 323 (14.9%) | 140 (13.9%) | 183 (15.8%) | .21 |
| Coronary artery disease | 1307 (60.5%) | 594 (59.0%) | 713 (61.7%) | .19 |
| Heart failure | 338 (15.6%) | 175 (17.4%) | 163 (14.1%) | .04 |
| Prior non-fatal MI | 487 (22.5%) | 254 (25.2%) | 233 (21.1%) | <.01 |
| Prior stroke | 170 (7.9%) | 72 (7.2%) | 98 (8.5%) | .25 |
| Rutherford class I | 3 (0.1%) | 2 (0.2%) | 1 (0.1%) | .22 |
| Rutherford class II-III | 1197 (55.4%) | 584 (58.0%) | 613 (53.1%) | |
| Rutherford class IV-VI | 583 (27.0%) | 261 (12.1%) | 322 (27.9%) | |
| Rutherford class unknown | 379 (17.5%) | 160 (15.9%) | 219 (19.0%) | |
| Ankle-brachial index | 0.75 ± 0.23 | 0.72 ± 0.19 | 0.77 ± 0.23 | <.001 |
| Toe-brachial index | 0.51 ± 0.28 | 0.47 ± 0.23 | 0.53 ± 0.28 | .34 |
| Medications | ||||
| Aspirin | 1180 (54.6%) | 625 (62.1%) | 555 (41.6%) | <.001 |
| Dual-antiplatelet therapy | 646 (29.9%) | 328 (32.6%) | 318 (27.5%) | .01 |
| Clopidogrel | 623 (28.9%) | 302 (30.0%) | 321 (27.8%) | .26 |
| Anticoagulation therapy | 120 (5.6%) | 56 (5.6%) | 64 (5.5%) | .98 |
| Warfarin | 74 (3.4%) | 34 (3.4%) | 40 (3.5%) | .91 |
| Cilastazol | 59 (2.7%) | 37 (3.7%) | 22 (1.9%) | .01 |
| Lipid-lowering therapy | 1139 (52.7%) | 596 (59.2%) | 543 (47.0%) | <.001 |
| Statin therapy | 1090 (50.4%) | 580 (57.6%) | 510 (44.2%) | <.001 |
| ACEI/ARB | 862 (39.9%) | 475 (47.2%) | 387 (33.5%) | <.001 |
| Beta-blockers | 857 (39.6%) | 472 (46.6%) | 385 (33.3%) | <.001 |
Data presented as mean ± standard deviation or number (%).
Stent-based and non-stent procedures completed 1-year follow-up. P-values based on Chi-square statistics. ACEI/ARB = angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers; MI = myocardial infarction.